Prostatype Genomics ABOMXSTO: PROGEN

Prostatype Genomics provides financing update

· Issued by Prostatype Genomics AB

Summary by 6ix AI

Prostatype Genomics AB, which sells Prostatype, a genetic test meant to support treatment decisions for prostate cancer patients, said on June 29, 2026 that its Board of Directors resolved to carry out a capital raising in Sweden of approximately SEK 47.4 million before transaction costs.

Key details

  • The board acted under an authorization granted by the Annual General Meeting held on June 22, 2026.
  • Subscription and underwriting commitments correspond to approximately 70 percent of the contemplated transaction.
  • The financing has three stages: an initial rights issue (a sale of new shares) accompanied by two separate series of warrants (rights to buy shares later).
  • With full subscription of the rights issue and full exercise of both warrant series, the company may receive total gross proceeds of more than SEK 106 million before transaction costs.
  • The company says the money is to support its continued Medicare reimbursement approval process, commercialization in the United States and Europe, and general corporate purposes. The offer is conducted in Sweden under Swedish law, and no securities are offered to the public in the United States.

What’s still pending

  • Both warrant series are expected to be exercisable during 2026.
  • Proceeds of more than SEK 106 million depend on full subscription of the rights issue and full exercise of both warrant series.

6ix AI wrote this summary from the release below and checked it against the release.

Prostatype Genomics AB provides financing update
Press Release
OTC Disclosure & News Service | 06/30/2026
On 29 June 2026, Prostatype Genomics AB announced that its Board of Directors has resolved, pursuant to the authorization granted by the Annual General Meeting held on 22 June 2026, to carry out a capital raising transaction in Sweden of approximately SEK 47.4 million before transaction costs.

The financing is supported by subscription and underwriting commitments corresponding to approximately 70 percent of the contemplated transaction.

The financing is structured in three stages. The initial rights issue is accompanied by warrants of two separate series. Both warrant series are expected to be exercisable during 2026. Assuming full subscription of the initial rights issue and full exercise of both warrant series, the Company may receive aggregate gross proceeds of more than SEK 106 million before transaction costs.

The purpose of the financing is to support the Company's continued Medicare reimbursement approval process and commercialization activities in the United States and Europe, as well as general corporate purposes.

The transaction is being conducted in Sweden in accordance with applicable Swedish law and is directed solely to persons who may lawfully participate under applicable laws and regulations. No securities are being offered to the public in the United States.

This press release is provided for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or in any other jurisdiction where such offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereof.

For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com

About Prostatype Genomics
Prostatype® is a genetic test intended to support treatment decision-making for patients diagnosed with prostate cancer. The test was developed by a research group at Karolinska Institutet and is commercialized by Prostatype Genomics AB.

Prostatype Genomics AB on 6ix

Story so far

Earlier from Prostatype Genomics

Later from Prostatype Genomics

All Prostatype Genomics news releases